Skip to content
- HGG include grade 3 and grade 4 tumors such as anaplastic astrocytoma, anaplastic oligodendroglioma, and Glioblastoma Multiforme (GBM).
- Three drugs have received full approval from the US FDA for brain cancer. Click to read more about approved brain cancer drugs.
- Each year, there are over 11,000 newly diagnosed cases of HGG in the US.
- GBM, the most common form of HGG, has an annual incidence of approximately 9,000 in the US and almost all GBM tumors recur.
- GBM is a highly aggressive cancer that infiltrates surrounding brain tissue.
- GBM is the most deadly form of brain cancer with a 5 year survival of <5%.
- According to a population-based study, median survival in all patients diagnosed with GBM is approximately 10 months.
- Relatively, more years of productive life are lost in patients with GBM brain cancer than any other cancer.
- Temodar (temozolamide) is FDA approved for the treatment of GBM and anaplastic astrocytoma. In patients with GBM, temozolomide (Temodar) provides a median survival advantage of 10 weeks.
- Avastin (bevacizumab) is FDA approved for the treatment of recurrent GBM. Currently, there are no data demonstrating increased survival with bevacizumab (Avastin).